肺動脈塞栓症(Pulmonary Embolism)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pulmonary Embolism Overview 6
Therapeutics Development 7
Pipeline Products for Pulmonary Embolism – Overview 7
Pipeline Products for Pulmonary Embolism – Comparative Analysis 8
Pulmonary Embolism – Therapeutics under Development by Companies 9
Pulmonary Embolism – Therapeutics under Investigation by Universities/Institutes 10
Pulmonary Embolism – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Pulmonary Embolism – Products under Development by Companies 14
Pulmonary Embolism – Products under Investigation by Universities/Institutes 15
Pulmonary Embolism – Companies Involved in Therapeutics Development 16
Bayer AG 16
Bristol-Myers Squibb Company 17
Daiichi Sankyo Company, Limited 18
F. Hoffmann-La Roche Ltd. 19
Pulmonary Embolism – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 27
apixaban – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
edoxaban tosylate – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
rivaroxaban – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SMTP-7 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TRX-1 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Pulmonary Embolism – Recent Pipeline Updates 39
Pulmonary Embolism – Dormant Projects 60
Pulmonary Embolism – Discontinued Products 61
Pulmonary Embolism – Product Development Milestones 62
Featured News & Press Releases 62
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 62
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 63
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 64
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 65
Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014 66
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 66
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 68
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 69
Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention 69
Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73